Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down – Here’s Why

Rapport Therapeutics (NASDAQ:RAPP) shares gapped down before the market opened on Monday . The stock had previously closed at $14.81, but opened at $14.06. Rapport Therapeutics shares last traded at $13.88, with a volume of 7,822 shares.

Rapport Therapeutics Stock Performance

The business has a fifty day simple moving average of $20.26 and a two-hundred day simple moving average of $21.42.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new stake in shares of Rapport Therapeutics in the 3rd quarter worth about $83,000. Barclays PLC boosted its position in Rapport Therapeutics by 36.8% in the third quarter. Barclays PLC now owns 12,863 shares of the company’s stock valued at $264,000 after buying an additional 3,463 shares in the last quarter. Geode Capital Management LLC acquired a new stake in shares of Rapport Therapeutics during the third quarter worth approximately $4,133,000. State Street Corp bought a new position in shares of Rapport Therapeutics in the third quarter valued at approximately $1,189,000. Finally, Maven Securities LTD acquired a new position in shares of Rapport Therapeutics in the 3rd quarter worth approximately $613,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.